Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 15 of 6351
-
Can stem cells rebuild the brain after stroke?
Cure OngoingEvaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Phase 1/2 • Sponsor: Clarion Cells, Inc. • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
One-shot gene therapy aims to free hemophilia patients from constant infusions
Disease control CompletedThis Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a pr…
Phase 1/2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One-Time gene therapy shows promise for hemophilia a
Disease control CompletedThis Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a single antibiotic dose cut child mortality in niger?
Prevention CompletedThe MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 mo…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Time gene therapy fix fabry disease for years?
Cure Stopped earlyFabry disease is a rare, X-linked inborn error of glycosphingolipid metabolism caused by an abnormal gene encoding the α-galactosidase A (αGLA) enzyme. The αGLA enzyme is ubiquitously expressed throughout the body and is responsible for the breakdown of glycosphingolipids, defici…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
One-Time gene therapy aims to stop bleeding in severe hemophilia
Disease control OngoingC3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A (FVII…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat breast cancer in major trial
Disease control OngoingThis study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on en…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can engineered immune cells beat tough B-Cell cancers?
Disease control OngoingThe purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this d…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new antibody slow Alzheimer's decline?
Disease control OngoingThe reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial partic…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Can a shorter, targeted radiation course tame throat cancer?
Disease control Recruiting nowThis is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week cour…
Phase 3 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a single injection restore sight in a rare childhood blindness?
Cure OngoingPrimary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Seco…
Phase 1/2 • Sponsor: Atsena Therapeutics Inc. • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
One-Time gene therapy could slash bleeding in hemophilia b
Disease control OngoingThis study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce geneti…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can a smart brain implant outsmart depression?
Disease control Recruiting nowNeurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electric…
Sponsor: Andrew Krystal • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a single gene infusion rewrite the story of fabry disease?
Cure Stopped earlyThis is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Face and hand transplants: a bold new trial for devastating injuries
Disease control Recruiting nowThe purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic de…
Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a targeted pill outperform chemo for bile duct cancer?
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
One-Time gene therapy helps babies with rare muscle disease sit on their own
Disease control CompletedThis is a Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in participants with spinal muscular atrophy (SMA) Type 1 and who are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 ge…
Phase 3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC